Proxy Results, Amendments to Bylaws (Form 8-K)

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On August 14, 2026, shareholders of Silo Pharma, Inc. (the "Company") approved an increase to the number of authorized shares of the Company's common stock, par value $0.0001 ("Common Stock") from 6,666,667 shares to 250,000,000 shares as set forth below.

On August 14, 2026, the Company filed a Certificate of Amendment (the "Amendment") to its Articles of Incorporation to increase its authorized shares of Common Stock from 6,666,667 shares to 250,000,000 shares.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 14, 2026, the Company held its annual meeting of shareholders, (the "Annual Meeting") for the purpose of holding a shareholder vote on the proposals set forth below. A total of 697,308 shares of the Common Stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting.

At the Annual Meeting, the Company's shareholders (i) re-elected each of Eric Weisblum, Wayne Linsley, Kevin Munoz and Jeff Pavell as members of the Company's board of directors to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death; (ii) ratified the appointment of Salberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; (iii) approved an amendment to the Company's Articles of Incorporation to increase the number of authorized shares of our Common Stock from 6,666,667 to 250,000,000 (the "Common Stock Increase Proposal"); and (iv) approved the authorization for the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals (the "Adjournment Proposal").

The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting, as set forth in the Company's Definitive Proxy Statement, filed with the Securities and Exchange Commission on June 30, 2026, are as follows: